TY - JOUR T1 - Pharmacotherapy for Lung Cancer with Comorbid Interstitial Pneumonia: Limited Evidence requires Appropriate Evaluation JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00337-2022 SP - 00337-2022 AU - Yuriko Ishida AU - Satoshi Ikeda AU - Akimasa Sekine AU - Tomohisa Baba AU - Takashi Ogura Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/07/28/23120541.00337-2022.abstract N2 - We have read with interest the article entitled “Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges” by Kewalramani N et al. [1] About 10% of lung cancer patients are complicated with interstitial pneumonia (IP) and have a poor prognosis. Although there is a lack of evidence in this area, the article clearly summarizes the current status from epidemiology to treatment, and is very informative for clinicians. However, there were three points that could be misleading to the reader, especially in the description of pharmacotherapy.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflicts of interest: Akimasa Sekine has received honoraria for lectures from AstraZeneca, Ono, Eli Lily and Boehringer Ingelheim, outside the submitted work.Conflicts of interest: Satoshi Ikeda has received research funds from Chugai Pharmaceutical Co, Ltd. and AstraZeneca K.K., outside the submitted work. Honoraria received for lectures from Chugai Pharmaceutical Co, Ltd., Ono Pharmaceutical Co, Ltd., Boehringer Ingelheim, Eli Lilly K.K, Bristol-Myers Squibb, AstraZeneca K.K., Pfizer and Taiho Pharma, outside the submitted work.Conflicts of interest: Tomohisa Baba has received Honoraria for lectures from AstraZeneca, Daiichi-Sankyo and Boehringer Ingelheim, outside the submitted work.Conflicts of interest: Takashi Ogura has received Honoraria for lectures from Shionogi, Eisai and Boehringer Ingelheim, outside the submitted work.Conflicts of interest: Yuriko Ishida has nothing to disclose. ER -